SCHEMBL6370532

SCHEMBL6370532

CC(=O)Nc1cccc(-c2n[nH]c3cc([N+](=O)[O-])ccc23)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 3/20 0.76
TTK P33981 4/20 0.58
SMN1; SMN2 Q16637 1/20 0.57
MAPK8 P45983 2/20 0.54
AAK1 Q2M2I8 1/20 0.52
ABCG2 Q9UNQ0 2/20 0.51
AURKA O14965 4/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
AURKB Q96GD4 1/20 0.50
ABCB1 P08183 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
JAK3 P52333 1/20 0.47
MELK Q14680 1/20 0.47
DYRK1A Q13627 1/20 0.46
PDE5A O76074 1/20 0.46
PDE1A P54750 1/20 0.46
PDE1B Q01064 1/20 0.46
PDE3B Q13370 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23722435 0.86 MAP2K7 (1.00) MAP2K7AURKAMAPTHPGDAURKB
SCHEMBL1513036 0.78 MAPT (0.78) MAP2K7TTKSMN1; SMN2MAPK8MAPT
SCHEMBL2860859 0.77 MAP2K7 (0.59) MAP2K7SMN1; SMN2ABCG2MAPTHPGD
SCHEMBL10173063 0.76 SMN1; SMN2 (0.59) MAP2K7SMN1; SMN2ABCG2MAPTHPGD
SCHEMBL6377261 0.75 MAPT (0.64) MAP2K7MAPTHPGDMEN1KMT2A
SCHEMBL1248559 0.75 SMN1; SMN2 (1.00) SMN1; SMN2MAPTHPGDMEN1KMT2A
SCHEMBL14570456 0.73 MAP2K7 (0.55) MAP2K7SMN1; SMN2AURKAMAPTHPGD
SCHEMBL12073910 0.73 TTK (0.65) MAP2K7TTKMAPK8AURKAMAPT
SCHEMBL6788254 0.72 PARP1 (0.63) MAP2K7TTKMAPK8AURKAMAPT
SCHEMBL6376401 0.72 MAPT (0.61) MAP2K7TTKMAPTHPGDPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US claimed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP claimed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO claimed
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 MAP2K7 2688/4885TTK 4053/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.